"Pharmaceutical Speed Reading" Seymor Fly buys Henogen Ossecom injection tymo...

January 18, 2021 / Medical Information At a Glance: Seymor Fly's 725 million euro acquisition of Henogen; Daily fresh medicine news, speed reading society and you pay attention to! Part1 Policy Brief Beijing added 2 new local confirmed cases From 0:00 to 24:00 on January 17 in Daxing District, there were 2 new locally confirmed cases, no new suspected cases and no asymptomatic infections;
two locally confirmed cases are located in the streets of Tiangong Hospital in Daxing District, with comprehensive epidemiological history, clinical manifestations, laboratory testing and imaging examination results, which were diagnosed as confirmed cases on the same day and clinically typed as normal.
Another imported case was in Serbia, departing from Serbia on 11 January and arriving at Beijing Capital Airport on 12 January on Air China flight CA878, where customs were health screening and nucleic acid testing, which turned negative and was sent to a central isolation hotel through closed-loop management.
tested positive for nucleic acid on 17 January.
relevant departments have carried out epidemiological investigations into the above-mentioned confirmed cases and implemented control measures as required.
(CCTV News) Heilongjiang added 7 new cases of confirmed 81 new cases of asymptomatic infection January 18, CCTV reporters from Heilongjiang Province Health Committee was informed that January 17, 2021 0-24, Heilongjiang Province, new crown pneumonia confirmed cases of 7 cases (4 cases in Anda City, 2 cases in Beilin District, Yuhua City, no symptoms of infection into a confirmed case).
1 case was cured and discharged from hospital (Aihui District, Heihe City).
81 new cases of asymptomatic infection were reported (74 cases in Wangkui County, Yuhua City, 2 cases in Qinggang County, Harbin City, Songbei District, 3 cases in Angxi District, Qiqihar City).
(CCTV News) Jilin Songyuan added a new case of asymptomatic infection for the 4th nucleic acid test screening found on January 18, according to the "Songyuan release" news, today 0-12 hours, Songyuan City, Jilin Province, a new case of asymptomatic infection, for January 14 Songyuan City reported asymptomatic infection 1 close contacts, is isolated medical observation during the active 4th nucleic acid test screening found.
the infected person in the city's designated treatment hospital isolation medical observation.
city of Matsuhara is tracking the epidemiological investigation of its close contacts and sub-secret contacts, and strictly implementing control measures.
(Caixin) lied about the full negative! A third-party agency was investigated on January 17 at 18:00, the city of Yantai, Hebei Province held a press conference on epidemic prevention and control, to introduce the latest situation of epidemic prevention and control.
, a member of the Standing Committee of the Yantai Municipal Committee and Minister of Propaganda, said that according to the Longyu County report, due to limited testing capacity, the collection of samples entrusted to a unit in Jinan.
14, the company lied to the health department about the full negative.
positive samples were reported on the morning of the 16th.
County has immediately launched emergency plans for this, resampling the 10 people involved, and immediately sealing and managing the tobacco company's family homes, a total of 19 households.
beijing news agency reported today that the third-party testing agency behind the underreporting was punished by the health care commission in April last year.
(Xinhua) -- Bayer's two best-selling products, the blood thinner Xalreto and the eye drug Eyelea, are at risk of expiring patent protection at a time when revenues from Bayer Pharmaceuticals are seeing a gap in revenue from Xalreto and Eylea patent protection expired.
patent break for the two heavy-duty drugs will lead to a revenue gap at Bayer, the head of Bayer's pharmaceutical business said, and the company's existing production line projects will not be able to fill the revenue decline for years to come.
announced the completion of its acquisition of Henogen, a viral carrier manufacturing business in Belgium for life sciences services and technology provider Novosep, after the company's 725 million euro acquisition of Henogen.
the deal was sold in cash at 725 million euros.
reported that Henogen's business will be part of ThermoFei's pharmaceutical services business, which is part of laboratory products and services.
(Sina Pharmaceutical News) Xi Xiang Technology completed nearly 10 million yuan angel round financing January 18, arterial network first learned that Xi Xiang Technology announced the completion of nearly 10 million yuan angel round financing, the current round of financing by Shanghai Jiuhe Tang Chinese Medicine Co., Ltd., Xiamen Spectrum Co., Ltd.
will be used for next-generation product development and digital service system construction.
(Arterial Network) Toro Bio filed an IPO application on NASDAQ recently, nasdaq official website news, Toro Bio submitted a NASDAQ listing application to the U.S. Securities and Exchange Commission, with a proposed capital raising of $100 million.
, according to a press release, the company filed for an IPO with JPMorgan Chase, Goldman Sachs Group Inc. and Cowen Co.
founded in 2016, to develop new treatments for chronic liver diseases such as NASH, liver fibrosis and hepatocellular carcinoma.
medical mission( medical mission) Becon Medical is about to go public market news that Beikang Medical has passed the listing hearing, the total amount of planned fund-raising is up to 250 million U.S. dollars (about 1.95 billion Hong Kong dollars).
, according to the prospectus, Beikang Medical is a unicorn company with an assisted reproductive genetic testing solution in China and the first company in China to have a high-volume gene sequencing product line covering the entire reproductive cycle.
public information shows that Beckon Medical's PGT-A kit can screen embryos for normal development before implantation, which is the first and first high-volume gene sequencing kit approved by the State Drug Administration, marking the birth of China's PGT three-generation IVF "documented" industrial genetic testing market.
(Saibai Blue) Jiang Bio today listed on the issue price of 43.22 yuan / share January 18, according to the exchange announcement, Jiang Bio today in Shanghai Stock Exchange, the company's securities code is 688317, the issue price of 43.22 yuan / share, the issue price-earnings ratio of 189.85 times.
(Shanghai Securities News) Part3 Pharmaceutical News GSK released positive data on dostarlimab in dMMR solid tumors January 16, GSK announced the latest data from the GARNET study F queue, mainly used to assess the role of dostarimab in mismatch repair defects of non-endometrial advanced solid tumors, the study is currently published at the 2021 American Society of Clinical Oncology gastrointestinal tumor symposium.
results showed that the objective remission rate of patients with DMMR advanced solid tumors treated with dostarlimab was 38.7%.
, after 12.4 months of medium follow-up, the medium remission duration was not reached, and all types of tumors had lasting remission.
(Sina Pharmaceutical News) Hesco: HSK-3486 U.S. Phase III clinical trial application obtained FDA approval January 18, Hesco announced that the fourth-tier subsidiary of Hesco Pharmaceuticals of the United States to the FDA HSK-3486 emulsion Phase III clinical trial application was recently approved by the FDA, will be officially launched.
the phase III trial in the United States, the adaptation is Induction of General Anesthesia, which is scheduled to join a group of 351 subjects, and applications for clinical trials in Europe are progressing as planned.
for other adaptations are also progressing as planned.
(Hesco Announcement) the world's 2nd 3D printed drug! The company's first 3D-printed drug product, T19, has been approved by the FDA for a new drug clinical trial.
is the world's second 3D-printed drug to submit IND to the FDA and the first 3D-printed drug product in China to enter the registration filing phase.
T19 is a 3D-printed drug designed and developed by San Diego with global intellectual property rights.
the product is designed for circadian rhythms for rheumatoid arthritis symptoms based on the principles of time therapy.
patients take T19 before bedtime, the concentration of drugs in the blood peaks in the morning when symptoms of pain, joint stiffness and dysfunction are most severe, and their daytime blood concentration is maintained for optimal drug treatment.
(Pharmaceutical Rubik's Cube) Cosing Zhongwei new crown inactivated vaccine in Brazil was approved for emergency use on January 17 local time, ANVISA announced that the company developed by Cosing Holdings "new crown inactivated vaccine" Kellefort emergency use permit in Brazil, Brazil's first batch of new crown vaccination on the same day kexing vaccine.
an ANVISA executive unanimously voted to adopt the resolution at a special meeting on the same day.
addition to Kelleford, the new crown vaccine developed by Oxford University and AstraZeneta UK was granted emergency approval on the same day.
, said the current outbreak situation in Brazil is serious.
scientific research data show that both vaccines meet the quality and safety requirements for emergency use.
(immediate drug news) Osaikang injection with thymosamine class 3 imitation listing application was approved on January 18, NMPA official website updated the approved drug information, Osaikang injection tymoamine class 3 imitation listing application was approved and treated as a review.
January 2019, Hengrui announced that the company's injection of 3 types of tymoamine imitation was approved and won the domestic first imitation.
, the capsules and injections of tamoamine have been evaluated by two enterprises, and the oral regular release dosage form has been included in the fourth batch of national collection catalog.
(Minenet) Yangzijiang propofol medium / long chain fat milk injection 4 imitation listing application was approved on January 18, NMPA official website news said that Yangzijiang propofol / long chain fat milk injection 4 imitation listing application was approved and treated as reviewed.
meters intranet data show that propofol medium/long chain fat emulsion is China's public medical institutions terminal nearly 2 billion anaesthetic varieties, the product has been included in the fourth batch of national collection.
there are currently two fat milk-carrying systems available worldwide: propofol injections (long-chain fat milk) and propofol medium/long-chain fat emulsions.
(Minenet) Jianjin Pharmaceutical Injection Phentamostin hydrochloride by the State Drug Administration drug registration certificate January 18, Jianyou shares issued a notice that its subsidiary Jianjin Pharmaceutical Products recently received NMPA on the approval of the issuance of injection phenylastamin drug registration certificate notice.
injection of benzodiacyte hydrochloride, an alkane agent, mainly used in chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, the original drug was first listed in the United States in 2008, the applicant is CEPHALON, specifications of 25mg/bottle, 100mg/bottle, of which 100mg specifications of the original drug was approved in China in 2018, 25mg specifications only Zhengdatian Pharmaceutical Group, a generic pharmaceutical company.
(Jianyou share announcement) Colum Pharmaceuticals: Medium/ long-chain fat milk injections through generic drug consistency evaluation January 18, Colum Pharmaceuticals announced that recently approved by the NMPA issued a chemical "medium/long-chain fat emulsion" "Drug Supplemental Application Approval Notice", drugs through generic quality and efficacy consistent evaluation, for patients in need of intravenous nutrition to provide energy and essential fatty acids.
medium/long chain fat emulsion is the most widely used fatty milk in clinical practice, with rapid energy supply, high efficiency nitrogen saving, liver protection and other advantages, has been widely recommended by domestic and foreign guidelines for liver function damage and tumor and other patients.
(Colum Pharmaceuticals Announcement) Ruishun Bio: The first foreign DNT cell drug to treat relapsed and difficult to treat acute myeloid leukemia was approved clinically it is known that the allogeneic DNT cell product RC1012 injectable developed by Ruishun Bio in November 2020 has obtained the clinical trial of the Drug Review Center of the State Drug Administration implied permission to develop adaptive disorders for relapsed recurring recurring difficulty in treating acute myeloid leukemia.
the product, which comes from healthy donors and does not require HLA (human leukocyte antigen) form, is expected to be the first innovative global heteroenmmune cell drug to treat relapsed acute myeloid leukemia.
(Arterial Network) Huitai Medical: obtained two medical device registration certificates January 18, Huitai Medical announced that recently, the company's wholly-owned subsidiary Hunan Epte Medical Devices received two medical device registration certificates issued by NMPA, the product name is "anchor balloon expansion catheter", "guide tube."
the anchoring balloon expansion catheter is the first innovative medical device in China to use balloon anchoring in the guide tube for catheter exchange.
(Whittay Medical Bulletin) Grigg Ingham and Cree Gene have teamed up to develop a new AAV vector, Grigg Ingham and Cree Gene, today announced a collaboration to develop a new gland-related viral vector for next-generation gene therapy through Cree Gene's proprietary VELPTM platform.
this new collaboration combines Grigg Ingham's experience in disease mechanism research and gene therapy development with Cree Gene's expertise in virus library building and efficient in vivo AAV screening to provide patients with potentially safer and more efficient new AAV serotypes.
(A.M.) Dano Pharmaceuticals hand in hand with Johnson and Johnson to jointly develop a new drug for non-tuberculosis branch bacillus on January 18, Danno Pharmaceuticals announced a partnership with Johnson and Johnson's Janssen Pharmaceuticals.
the agreement, the latter will use the former's multi-target joint molecular new drug development platform to jointly find a new combination therapy for non-tuberculosis branch infection.
According to the Guidelines for diagnosis and treatment of mycobacteria non-TB (2020 edition), NTM refers to Mycobacteria tuberculosis, which is other than mycobacteria and mycobacteria leprosy, most commonly invades the lungs of the human body, and has clinical manifestations similar to tuberculosis, including systemic symptoms and local damage, and has a higher incidence in patients with underlying lung disease or immune system disease.
(Biological Discovery) Development of Innovative Ophthalmology Gene Therapy ViGeneron and First Third Co., D.C. On January 18, ViGeneron announced a research collaboration with Phase 13, using its proprietary, modified adeno-related viral vector to deliver a new therapeutic protein with a view to developing a treatment for common ophthalmology